AGIO
Agios Presents Positive Results From Phase 3 Energize-T Study of Mitapivat at Ash 2024 and Provides Regulatory Update on Mitapivat
时间：2024-12-09 01:40:00 市场： 美股 综合
Agios Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $56 From $60
时间：2024-09-27 18:06:17 市场： 综合 美股
Agios Pharmaceuticals Shares up 5% After Rival Pfizer Withdraws Sickle Cell Disease Treatment
时间：2024-09-26 21:55:54 市场： 美股 综合
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (Ag-946) for Treatment of Myelodysplastic Syndromes (Mds)
时间：2024-09-11 19:00:01 市场： 美股 综合